Skip to content
Bored Studies
RecruitingPhase 3

An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin

Adneuris Therapeutics, Inc. · NCT07845071

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
160
US sites recruiting
15
Study start
September 22, 2026
Record last updated
October 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.

Being studied: Cebranopadol 400 ug

Conditions: Pain

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Adults 18 to 75 years of age.
  • Able to provide informed consent.
  • Experiencing moderate to severe acute pain related to: 1) An ambulatory surgical procedure expected to cause pain lasting at least 72 hours, or 2) A traumatic or non-traumatic musculoskeletal condition.
  • Have a pain score of at least 4 on a 0 to 10 pain rating scale before starting study treatment.
  • Willing and able to comply with study requirements

Exclusion Criteria

  • Chronic pain condition that requires ongoing pain medication.
  • Significant medical or psychiatric condition that could affect participation or study results.
  • History of substance use disorder or misuse of alcohol or drugs.
  • Current use of medications that may interfere with the study drug or pain assessments.
  • Known allergy or intolerance to cebranopadol or permitted rescue pain medications.
  • Pregnant or breastfeeding.
  • Participation in another clinical trial or receipt of an investigational drug within the protocol-defined period before study entry.
  • Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study assessments.

Recruiting US locations

Study contacts (from the official record)

  • Study Director, Adneuris Therapeutics · 732-940-2800 · clinicaltrials@trispharma.com
  • Emilio Quetglas, MD · 732-940-2800 · clinicaltrials@trispharma.com
All pain studies in Arizona →
An Open-Label, Safety and Efficacy Study of Cebranopadol in… (NCT07845071) | Bored Studies